Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience.
Int. J. Radiat. Oncol. Biol. Phys., Dec;81(5):1374-9 (2011)
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
J. Clin. Oncol., Oct;28(28):4324-32 (2010)
Treatment strategies in limited stage follicular NHL.
Best Pract Res Clin Haematol., Jun;24(2):179-86 (2011)
Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.
Radiat Oncol., 7:5 (2012)
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
Blood., Jul;114(5):1099-109 (2009)
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
J. Am. Acad. Dermatol., Dec;59(6):953-7 (2008)
Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin.
Am. J. Surg. Pathol., Apr;33(4):591-8 (2009)
Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome.
Arch Dermatol., Jun;145(6):667-74 (2009)
Hodgkin's lymphoma: the role of radiation in the modern combined strategies of treatment.
Hematol. Oncol. Clin. North Am., Oct;21(5):915-27 (2007)
Tolerance and chimerism after renal and hematopoietic-cell transplantation.
N. Engl. J. Med., Jan;358(4):362-8 (2008)
Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease.
J. Am. Acad. Dermatol., Oct;59(4):706-12 (2008)
Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Arch Dermatol., Jan;143(1):45-50 (2007)
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Resear
Blood., Jul;110(2):479-84 (2007)
Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course.
J. Clin. Oncol., Apr;19(8):2179-88 (2001)
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.
J. Clin. Oncol., Feb;20(3):630-7 (2002)
Primary radiotherapy for localized orbital MALT lymphoma.
Int. J. Radiat. Oncol. Biol. Phys., Mar;52(3):657-63 (2002)
Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation.
Transplantation., May;73(9):1386-91 (2002)
Hodgkin's disease: a model for interdisciplinary cancer management: 2002 Janeway lecture.
Cancer J., 8(6):425-31 (2002)
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
Blood., Jun;101(11):4285-9 (2003)
Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
Arch Dermatol., Feb;139(2):165-73 (2003)